By combining, in a liposome, magnetic nanoparticles and photosensitizers that are simultaneously and remotely activated by external physical stimuli (a magnetic field and light), scientists obtained total tumor regression in mice.
Non-toxic when they are not activated, such therapies can also achieve a reduction in adverse effects. These results demonstrate the importance of multiple treatments.
One of the strategies employed to limit the adverse effects of cancer therapies is the development of nanocarrier systems that can convey active ingredients to target tumor cells. These are referred to as “physical” therapies when the active substances, molecules or nanoparticles, can be remotely activated by external physical stimuli — in this case by light or a magnetic field. In this context, the study team developed a new type of carrier that combines photosensitivity and magnetism. To achieve this, they first encapsulated magnetic nanoparticles in the inner compartment of a liposome in sufficient quantities to render it ultra-magnetic, before incorporating photosensitizers into its lipid bilayer, while preserving an optimum size for circulation in the blood.
These liposomes, containing magnetic nanoparticles and photosensitizers, were injected directly into the tumor in the mouse model. The scientists thus combined two techniques to achieve complete destruction of cancer cells. The first one, magnetic hyperthermia, consists in exciting the nanoparticles with a magnetic field to raise the temperature of the tumor and destroy it.. The second method, photodynamic therapy, is made possible by the photosensitizers, which, when activated, release reactive oxygen species that are toxic to tumor cells. These two physical therapies act in synergy on the activity of the proteins involved in apoptosis, or programmed cell death. Their combination thus induces total regression of the tumor, while a single therapy is not able to stop its growth.
Read more: Combining magnetism and light to fight cancer
The Latest on: Tumor regression
[google_news title=”” keyword=”Tumor regression” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Tumor regression
- Surgery best bet for Husky’s conditionon May 11, 2024 at 9:17 pm
My male White Husky is almost 14. About two weeks ago, I noticed that he started reaching for his rear end a lot and seemed painful and uncomfortable.
- Cancer Vaccine Triggers Fierce Immune Response to Fight Malignant Brain Tumors in Human Patientson May 11, 2024 at 6:37 am
In the first human trial, an mRNA cancer vaccine at the University of Florida triggered immune systems to fiercely attack glioblastoma.
- Radical Cystectomy Outcomes Linked to Preoperative Potassium Levelson May 9, 2024 at 4:59 pm
On multivariable Cox regression analyses adjusted for perioperative parameters, abnormal preoperative PPLs were significantly associated with 1.9-, 2.8- and 2.1-fold increased risks for all-cause ...
- Higher consumption of ultra-processed foods linked to elevated mortality riskon May 9, 2024 at 3:26 am
Large-scale cohort studies suggest that ultra-processed foods have negative health impacts, such as overweight or obesity, cardiovascular disease, type 2 diabetes, colon cancer, metabolic syndrome, ...
- Study identifies disparities in end-of-life care for lung cancer patientson May 8, 2024 at 9:07 am
Patients with lung cancer who were Asian/Pacific Islander, Black or Hispanic experienced a higher intensity of end-of-life care compared to white patients, according to a Northwestern Medicine ...
- Atherosclerosis Progression May Share Traits With Tumor Growthon May 7, 2024 at 5:00 pm
In mouse models, they found, niraparib slowed down the progression of atherosclerosis and induced regression of lesions in advanced disease. “Our findings demonstrate that atherosclerosis is an ...
- Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updateson May 7, 2024 at 1:05 pm
Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial ...
- SILUAN: The childhood cancer detection acronym everyone should knowon May 7, 2024 at 2:00 am
Early detection is crucial for childhood cancers, which is why all parents and caregivers should know which signs to look out for.
- MicroRNAs May Predict Pancreatic Cancer Risk Years Before Diagnosison May 3, 2024 at 7:15 am
Expression levels of several microRNAs in plasma samples can help predict the onset of pancreatic cancer up to 5 years prior to clinical diagnosis.
- Tool May Help Prioritize High-Risk Patients for Hysteroscopyon May 1, 2024 at 2:53 am
A new nomogram is intended to identify patients at high risk for endometrial cancer and prioritize them in the hysteroscopy waiting list.
via Bing News